Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

NCT04471428 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

366

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Cabozantinib
DRUG: Atezolizumab
DRUG: Docetaxel

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]